TERRI STEELE: Open Payments
NPI 1730108192 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,272 in 57 payments from 13 companies in 2025. Trend: 2023 $1,471 · 2024 $1,605 · 2025 $1,272
Food & beverage: $1,171Education: $101
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $255 |
| ABBVIE INC. | 20 | $224 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $179 |
| Vanda Pharmaceuticals Inc. | 5 | $147 |
| Teva Pharmaceuticals USA, Inc. | 3 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $85 |
| Supernus Pharmaceuticals, Inc. | 3 | $64 |
| Axsome Therapeutics, Inc. | 2 | $57 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $45 |
| Alkermes, Inc. | 1 | $24 |
Products named: REXULTI, VRAYLAR, CAPLYTA, FANAPT, TRINTELLIX, Qelbree, Auvelity, AUSTEDO XR.
Industry payments across AL — which companies pay providers there.
